# A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)

> **NCT00541463** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 330 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks
- **DRUG:** Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks

## Key facts

- **NCT ID:** NCT00541463
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** —
- **Final completion:** 2003-05
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00541463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00541463, "A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00541463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*